Catanzaro, Italy

Pierfrancesco Tassone

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 1.6

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016-2024

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Pierfrancesco Tassone: Innovator in Monoclonal Antibody Development

Introduction

Pierfrancesco Tassone is a notable inventor based in Catanzaro, Italy. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 4 patents to his name, his work is recognized for its potential impact on cancer treatment.

Latest Patents

One of his latest patents is focused on a monoclonal antibody targeting a unique sialoglycosylated cancer-associated epitope of CD43. This invention involves a monoclonal mouse antibody produced by a hybridoma cell, which has been deposited under ICLC accession number ICLC PD n° 16001. The antibody comprises a heavy chain variable region with complementarity determining regions CDRH1, CDRH2, and CDRH3, as well as a light chain variable region with complementarity determining regions CDRL1, CDRL2, and CDRL3. The specific amino acid sequences for these regions are GFTFSSFGMH (SEQ ID NO: 1), YISSGSGNFYYVDTVKG (SEQ ID NO: 43), STYYHGSRGAMDY (SEQ ID NO: 3), SASSSVSSMYWY (SEQ ID NO: 4), DTSKMAS (SEQ ID NO: 5), and QQWSSYPPIT (SEQ ID NO: 6). This invention also includes antibodies that recognize the same epitope.

Career Highlights

Pierfrancesco Tassone has worked at the Università Degli Studi Magna Graecia Catanzaro, where he has contributed to various research initiatives. His work has been instrumental in advancing the understanding of cancer-associated epitopes and their potential therapeutic applications.

Collaborations

He has collaborated with notable colleagues such as Pierosandro Tagliaferri and Maria Teresa Di Martino. These collaborations have further enriched his research and development efforts in the field of biotechnology.

Conclusion

Pierfrancesco Tassone's innovative work in monoclonal antibody development showcases his commitment to advancing cancer treatment. His contributions are significant in the ongoing fight against cancer, and his patents reflect a dedication to scientific progress.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…